News | December 03, 2013

International Study Finds Heart Disease Similar in Men, Women

Computed tomography scan of the heart, allowing 3-D views of cardiac anatomy, including the coronary arteries.


December 3, 2013 — An analysis of data from an international multicenter study of coronary computed tomography angiography (CCTA) reveals that men and women with mild coronary artery disease (CAD) and similar cardiovascular risk profiles share similar prognoses. Results of the study were presented at the Radiological Society of North America Annual Meeting (RSNA 2013).
 
"We conducted this study because we wanted to understand whether men and women with the same extent of coronary artery disease and similar risk profiles have similar or dissimilar prognoses," said Jonathon Leipsic, M.D., FRCPC, director of medical imaging, St. Paul's Hospital in Vancouver, British Columbia. "There is a tendency to think women's heart disease is very different than men's heart disease. Our data show that once plaque accumulates in the coronary arteries, the prognosis is very similar between men and women."
 
For the study, Leipsic and a team of researchers used data from the Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter (CONFIRM) Registry, which collected information on 27,725 individuals in six countries who underwent CCTA. The registry also included participants' traditional risk factors, allowing for the derivation of Framingham scores, which are used to determine an individual's risk of developing cardiovascular disease.
 
From the registry, the researchers identified 18,158 patients without known CAD whose CCTA results were normal or indicated nonobstructive disease, in which coronary arteries were less than 50 percent blocked. These patients, including 8,808 women and 9,350 men, were then matched on the basis of pre-existing cardiovascular risk factors and the extent of their CAD as determined by CCTA, resulting in a one-to-one cohort of 11,462 patients.
 
A statistical analysis of the matched cohort revealed that, controlling for all cardiovascular risk factors, nonobstructive CAD conferred a similar adverse risk of death or heart attack in both men and women. Conversely, the absence of plaque on CCTA conferred a good prognosis for both men and women. Of the patients in the cohort, only 251 experienced a heart attack or cardiac-related death during an average follow-up period of 2.3 years.
 
"This analysis is exciting, because this has never been shown before," said Leipsic. "There's a prevailing belief that mild CAD puts women at greater risk for a major cardiac event compared to men with mild CAD. Our findings show this is just not true."
 
For more information: www.rsna.org

Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now